Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Ad26.RSV.preF vaccine efficacy study in adults aged 60 years and older
2020-005458-97Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and respiratory syncytial virus lower respiratory tract infection comparing Ad26.RSV.preF-based vaccine with Placebo (2 arms). Primary endpoint: First occurrence of RT-PCR-confirmed RSV-mediated lower respiratory tract disease. Started Jun 2021; status: terminated.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on 2020-005458-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005458-97.